GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Deferred Policy Acquisition Costs

SynAct Pharma AB (OSTO:SYNACT) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry
Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.